Health Care • Medical/Dental Instruments
$15.41 ▼ -0.24
(-1.53%)
MKT CAP: $484.0M • VOL: 491.9K
52W L $3 52W H $17
ROARABLE / RQD
D • 46/100
PIOTROSKI
4 / 9
RCEL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $71.6M | $64.3M | $50.1M |
| YoY Revenue Growth % | +11.5% | +28.1% | — |
| Gross Profit | $58.8M | $55.2M | — |
| Gross Margin % | 82.1% | 85.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$42.5M | -$56.6M | -$42.7M |
| Operating Margin % | -59.4% | -80.0% | -80.0% |
| Net Income (GAAP) | -$48.6M | -$61.8M | -$35.4M |
| EBITDA (Normalized) | -$41.7M | -$49.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$31.2M | -$48.9M | -$38.0M |
| Capital Expenditures (CapEx) | $1.0M | $9.2M | — |
| Free Cash Flow (FCF) | -$32.2M | -$58.1M | -$38.0M |
| FCF Margin % | -45.0% | -80.0% | -75.8% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $10.2M | $14.1M | — |
| Total Debt (Short + Long Term) | $0 | $42.2M | — |
| Total Stockholders' Equity | -$16.6M | $4.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RCEL.